.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
GCH1 (GTP Cyclohydrolase I) is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis. BH4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, and nitric oxide synthases. This page covers the structure, function, and disease relevance of GCH1 in neurodegenerative processes.
GCH1 (GTP cyclohydrolase I) catalyzes the first step in tetrahydrobiopterin (BH4) biosynthesis: the conversion of GTP to dihydroneopterin triphosphate. BH4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, and nitric oxide synthases. GCH1 is expressed in various tissues including the brain, where it supports dopamine and serotonin synthesis.
GCH1 forms a homodecamer composed of two pentameric rings. Each active site is at the interface between subunits. The enzyme requires zinc for stability and activity.
GCH1 (GTP cyclohydrolase I) catalyzes the first step in tetrahydrobiopterin (BH4) biosynthesis: the conversion of GTP to dihydroneopterin triphosphate. BH4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, and nitric oxide synthases.
GCH1 mutations cause dopa-responsive dystonia (DRD) and BH4-deficient hyperphenylalaninemia. GCH1 deficiency leads to reduced dopamine and serotonin synthesis. Heterozygous GCH1 mutations are a major cause of DRD, which responds dramatically to L-DOPA.
BH4 supplementation is used to treat GCH1-related disorders. Gene therapy approaches are in development. Small molecules that stabilize GCH1 or enhance residual enzyme activity are being explored. L-DOPA remains the primary treatment for neurological symptoms.
The study of Gch1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.